Tags : Infigratinib


BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib

Shots: BridgeBio to receive ~$2.45B+ including ~$100M in up front, regulatory and commercial milestones along with royalties on net sales of Infigratinib from Helsinn Group. The agreement is expected to close in Q2’21 Helsinn to co-commercialize infigratinib in oncology and other indications except for skeletal dysplasia indications in the US and will equally share profits […]Read More